Find information on thousands of medical conditions and prescription drugs.

Hypertension

Hypertension or high blood pressure is a medical condition where the blood pressure is chronically elevated. While it is formally called arterial hypertension, the word "hypertension" without a qualifier usually refers to arterial hypertension. more...

Home
Diseases
A
B
C
D
E
F
G
H
Hairy cell leukemia
Hallermann Streiff syndrome
Hallux valgus
Hantavirosis
Hantavirus pulmonary...
HARD syndrome
Harlequin type ichthyosis
Harpaxophobia
Hartnup disease
Hashimoto's thyroiditis
Hearing impairment
Hearing loss
Heart block
Heavy metal poisoning
Heliophobia
HELLP syndrome
Helminthiasis
Hemangioendothelioma
Hemangioma
Hemangiopericytoma
Hemifacial microsomia
Hemiplegia
Hemoglobinopathy
Hemoglobinuria
Hemolytic-uremic syndrome
Hemophilia A
Hemophobia
Hemorrhagic fever
Hemothorax
Hepatic encephalopathy
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatoblastoma
Hepatocellular carcinoma
Hepatorenal syndrome
Hereditary amyloidosis
Hereditary angioedema
Hereditary ataxia
Hereditary ceroid...
Hereditary coproporphyria
Hereditary elliptocytosis
Hereditary fructose...
Hereditary hemochromatosis
Hereditary hemorrhagic...
Hereditary...
Hereditary spastic...
Hereditary spherocytosis
Hermansky-Pudlak syndrome
Hermaphroditism
Herpangina
Herpes zoster
Herpes zoster oticus
Herpetophobia
Heterophobia
Hiccups
Hidradenitis suppurativa
HIDS
Hip dysplasia
Hirschsprung's disease
Histoplasmosis
Hodgkin lymphoma
Hodgkin's disease
Hodophobia
Holocarboxylase...
Holoprosencephaly
Homocystinuria
Horner's syndrome
Horseshoe kidney
Howell-Evans syndrome
Human parvovirus B19...
Hunter syndrome
Huntington's disease
Hurler syndrome
Hutchinson Gilford...
Hutchinson-Gilford syndrome
Hydatidiform mole
Hydatidosis
Hydranencephaly
Hydrocephalus
Hydronephrosis
Hydrophobia
Hydrops fetalis
Hymenolepiasis
Hyperaldosteronism
Hyperammonemia
Hyperandrogenism
Hyperbilirubinemia
Hypercalcemia
Hypercholesterolemia
Hyperchylomicronemia
Hypereosinophilic syndrome
Hyperhidrosis
Hyperimmunoglobinemia D...
Hyperkalemia
Hyperkalemic periodic...
Hyperlipoproteinemia
Hyperlipoproteinemia type I
Hyperlipoproteinemia type II
Hyperlipoproteinemia type...
Hyperlipoproteinemia type IV
Hyperlipoproteinemia type V
Hyperlysinemia
Hyperparathyroidism
Hyperprolactinemia
Hyperreflexia
Hypertension
Hypertensive retinopathy
Hyperthermia
Hyperthyroidism
Hypertrophic cardiomyopathy
Hypoaldosteronism
Hypocalcemia
Hypochondrogenesis
Hypochondroplasia
Hypoglycemia
Hypogonadism
Hypokalemia
Hypokalemic periodic...
Hypoparathyroidism
Hypophosphatasia
Hypopituitarism
Hypoplastic left heart...
Hypoprothrombinemia
Hypothalamic dysfunction
Hypothermia
Hypothyroidism
Hypoxia
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Persistent hypertension is one of the risk factors for strokes, heart attacks, heart failure and arterial aneurysm, and is a leading cause of chronic renal failure.

Definition

Blood pressure is a continuous variable, and risks of various adverse outcomes rise with it. A blood pressure of less than 120/80 mmHg is defined as "normal" in adults. Hypertension is usually diagnosed on finding blood pressure of 140/90 mmHg or above, measured on both arms on three occasions over a few weeks.

Recently, the JNC VII (The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) has defined blood pressure 120/80 mmHg to 140/90 mmHg as "prehypertension". Prehypertension is not a disease category. Rather, it is a designation chosen to identify individuals at high risk of developing hypertension (JNC VII).

In patients with diabetes mellitus or kidney disease studies have shown that blood pressure over 130/80 mmHg should be considered a risk factor and may warrant treatment.

Etiology

Essential hypertension

  • Age. Over time, the number of collagen fibres in artery and arteriole walls increases, making blood vessels stiffer. With the reduced elasticity comes a smaller cross-sectional area in systole, and so a raised mean arterial blood pressure.
  • High salt intake
  • Sedentary lifestyle
  • Tobacco smoking
  • Alcohol abuse
  • High levels of saturated fat in the diet
  • Obesity. In obese subjects, losing a kilogram of mass generally reduces blood pressure by 2 mmHg.
  • Stress
  • Low birth-weight
  • Diabetes mellitus
  • Various genetic causes

Secondary hypertension

While most forms of hypertension have no known underlying cause (and are thus known as "essential hypertension" or "primary hypertension"), in about 5% of the cases, there is a known cause, and thus the hypertension is secondary hypertension.

Pathophysiology

The mechanisms behind the factors associated with inessential hypertension are generally fully understood, and are outlined at secondary hypertension. However, those associated with essential hypertension are far less understood. What is known is that cardiac output is raised early in the disease course, with total peripheral resistance normal; over time cardiac output drops to normal levels but TPR is increased. Three theories have been proposed to explain this:

  • Inability of the kidneys to excrete sodium, resulting in natriuretic factor (note: the existence of this substance is theoretical) being secreted to promote salt excretion with the side-effect of raising total peripheral resistance.
  • An overactive renin / angiotension system leads to vasoconstriction and retention of sodium and water. The increase in blood volume leads to hypertension.
  • An overactive sympathetic nervous system, leading to increased stress responses.

Read more at Wikipedia.org


[List your site here Free!]


Treatment for secondary pulmonary hypertension
From CHEST, 10/1/05 by Charlie Strange

No therapy for idiopathic pulmonary fibrosis (IPF) has been proven to improve mortality or quality of life. However, like many diseases for which we now have cures, disease pathogenesis needed to be understood first before we could develop effective medications. Most of us have thought for a long time that pulmonary hypertension (PH) is a very bad marker of IPF severity. In this issue of CHEST (see page 2393), Nadrous et al (1) report on the outcome of a large cohort of patients at the Mayo Clinic showing that PH has a significant correlation with mortality due to IPF. While not surprising, there is certainly a more positive spin to these data that needs to be explored.

The primary IPF symptom is dyspnea. Despite the fact that FVC remains the most robust correlate of IPF prognosis, (2,3) the cause of exercise intolerance is not the associated limitation of exercise tidal volume. Instead, exercise intolerance is related more to cardiovascular limitations, including the oxygen desaturation associated with poor ventilation and perfusion matching. (4) Maybe, if we cannot change ventilation, we should explore methods to change perfusion.

The pathogenesis of PH in IPF has not been comprehensively studied. Historically, the feeling has been that lung fibrosis also envelopes some of the vasculature. Therefore, the treatment of secondary PH is to reverse lung fibrosis. At this level of understanding, the refractoriness of secondary PH to vasodilators is no surprise.

In patients with IPF, areas of honeycomb lung at the lung bases that involve the pulmonary vasculature will transition pulmonary artery blood flow toward the lung apex, an area of the lung that is more rarely involved with fibrosis. As > 50% of the vasculature is obliterated, pulmonary artery pressure will rise. The first possible detection of elevated pulmonary artery pressure will occur when exercise increases cardiac output through an increased pulmonary vascular resistance. Only later will resting echocardiography detect disease. Using this model, the height of systolic pulmonary artery pressure should mirror the extent of lung fibrosis.

However, in the case series by Nadrous et al, the correlation between FVC and pulmonary artery pressures as detected by echocardiography did not even reach statistical significance. The correlation with the diffusing capacity of the lung for carbon dioxide was present but not robust. If this is true, then we must redefine our understanding of PH in IPF patients. Some of this discordance may relate to cigarette smoking and falsely preserved FVC through air trapping. However, there is much that is not understood about this observation.

We will continue to debate the issue of whether echocardiography is sufficiently accurate for the diagnosis of pulmonary arterial hypertension. In secondary PH, the debate is just as robust. In the Mayo Clinic series, the subgroup in which PH could not be estimated because of the lack of tricuspid regurgitation did not have the longest survival time. Therefore, should we advance to clinical trials, right heart catheterization will be needed to accurately measure both left and right heart pressures.

Another interesting but disturbing observation is the very poor mortality rate observed in the subgroup of individuals with concomitant left ventricular dysfunction. Possibly, the preservation of cardiac output is as important in patients with IPF-associated PH as in those with idiopathic pulmonary arterial hypertension.

So, what will it take to change the fatalism with which many pulmonary physicians approach IPF? Since corticosteroid and antifibrotic therapies have not yet proven to be beneficial in randomized trials, might there be other options to improve IPF outcomes? Should we begin ordering serial echocardiography or measurements of brain natriuretic peptide levels5 to define the frequency of PH with rest and exercise as a target for therapy? The answer will be realized after the next round of clinical trials directed at IPF-induced PH, targeting functional outcomes.

Because IPF and most interstitial lung diseases are heterogeneous, some healthy blood vessels likely remain. These blood vessels, which are localized in areas of preserved lung parenchyma, might be amenable to vasodilator therapy, particularly if medial hypertrophy in response to pressure overload has developed. One challenge will be to match ventilation and perfusion to avoid worsened exercise hypoxemia.

There are other diseases in which so called fixed pulmonary artery hypertension has proven amenable to drug therapy. The response of thromboembolic PH (6,7) and sarcoidosis (8) to epoprostenol therapy serves as an example of how those blood vessels remaining in the lung may vasodilate and marginally improve cardiac output, pulmonary vascular resistance, and symptoms. Future trials in IPF patients will use the data of Nadrous et al to risk stratifying the patients and justify medication trials. These trials seem justified in the investigation of this devastating pulmonary disease.

REFERENCES

(1) Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with ideopathic pulmonary fibrosis. Chest 2005; 128:2393-2399

(2) King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164:1171-1181

(3) Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:543-548

(4) Lama VN, Flaherty KR, Toews GB, et. al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 1084-1090

(5) Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170:360-365

(6) Bresser P, Fedullo PF, Auger WR, et. al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23:595-600

(7) Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003; 123:338-343

(8) Jones K, Higenbottam T, Wallwork J. Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest 1989; 96:784-789

Charlie Strange, MD, FCCP

Charleston, SC

Dr. Strange is Professor of Pulmonary and Critical Care Medicine, Medical University of South Carolina.

Correspondence to: Charlie Strange, MD, FCCP, Professor of Pulmonary and Critical Care Medicine, Medical University of South Carolina, 812 CSB, 96 Jonathan Lucas St, Charleston, SC 29425; e-mail: strangec@musc.edu

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Hypertension
Home Contact Resources Exchange Links ebay